A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Florida Receives $4.3M to Help Rehabs Like Legacy Healing Center Combat the Opioid Epidemic

To provide "multifaceted support" for the treatment of opioid use disorder amidst the national opioid epidemic.

What To Know

  • The government funding for effective treatment for opioid use disorder in Florida aims to help offset the devastation that the COVID-19 pandemic has had on addiction rates and to continue providing support to those suffering from opioid use disorder.
  • And we are especially vulnerable and susceptible to depression, anxiety, and relapse because of the isolation, because of the quarantine, because of the fear, because of the disconnection.

The Substance Abuse and Mental Health Services Administration (SAMHSA), a branch of the U.S. Department of Health and Human Services, is set to distribute an additional $4.3 million to organizations across Florida to provide “multifaceted support” for the treatment of opioid use disorder amidst the national opioid epidemic. So far, SAMHSA has provided $123 million nationally to help healthcare providers and communities combat substance use disorder.

The main focus of this round of funding for opioid use disorder treatment is for Medication-Assisted Treatment for Prescription Drug and Opioid Abuse (MAT-PDOA), also known as medically-assisted treatment (MAT).

MAT programs provide a highly effective long-term treatment for opioid use disorder.  MAT can have a lasting impact on brain function, by improving brain function and preventing relapse while simultaneously addressing the root causes of substance abuse through evidence-based behavioral therapies.

Florida remains a hotbed in the opioid epidemic.  The state saw an alarming 59 percent increase in drug overdose deaths from 2019 to 2020, according to preliminary data released in the Project Opioid Tampa Bay report which called the opioid problem in Florida “the epidemic within the pandemic”.

The impact of the COVID-19 pandemic on mental health, substance use disorder, and recovery is still being felt by individuals and communities across Florida. The government funding for effective treatment for opioid use disorder in Florida aims to help offset the devastation that the COVID-19 pandemic has had on addiction rates and to continue providing support to those suffering from opioid use disorder.

David Levin, Chief Clinical Officer and CEO of Legacy Healing Center which operates in Florida and New Jersey, commented on the effects of the COVID-19 pandemic on addiction.  “The disease of addiction metastasizes in isolation. And we are especially vulnerable and susceptible to depression, anxiety, and relapse because of the isolation, because of the quarantine, because of the fear, because of the disconnection. [The COVID-19 pandemic] has had a tremendous impact and it’s affecting everybody,” he said.

Legacy Healing Center, a SAMHSA-recognized addiction treatment center, provides MAT programs and holistic treatment models that can help a person out of addiction and mental health disorders. With the new round of funding for treatment, the professional help Floridians need to overcome opioid use disorder is now more available than ever.

Anyone struggling with substance abuse can speak to a treatment specialist at any time by calling (888) 534-2295.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.